LUPIN LIMITED SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material

Manufacturer

Distributor

Tadalafil Tablets, USP 20 mg

Lupin Limited Nagpur 441 108 India

Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion	Expected to be non-combustible.			
Health	Do not use tadalafil in patients who are using any form of organic nitrate, either regularly or intermittently. Tadalafil potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway.			
	Do not use tadalafil in patients who are using a GC stimulator, such as riociguat. Tadalafil may potentiate the hypotensive effects of GC stimulators.			
	Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil or CIALIS. Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis.			
Environment	No information is available about the potential of this product to produce adverse environmental effects.			
Section 3: Composition/Information on Ingredients				
Section 3, Composition/information on ingredients				
Ingredients	CAS			
Tadalafil USP	171596-29-5			
SDS · 195/01	Page 1 of 5			

SDS : 195/01 Effective Date : 25/01/2019 Page 1 of 5

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion	Flush out mouth with water, consult a physician immediately.			
Inhalation	In case of inhalation remove to fresh air and seek medical aid.			
Skin Contact	Remove immediately contaminated clothes, wash affected skin with plenty of water.			
Eye Contact	In case of contact with eyes rinse thoroughly with plenty of water and get medical advice.			
NOTES TO HEALTH PROFESSIONALS				
Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.			
OVERDOSAGE	Single doses up to 500 mg have been given to healthy male subjects, and multiple daily doses up to 100 mg have been given to male patients with erectile dysfunction. Adverse reactions were similar to those seen at lower doses. Doses greater than 40 mg have not been studied in patients with pulmonary arterial hypertension. In cases of overdose, standard supportive measures should be adopted as needed. Hemodialysis contributes negligibly to tadalafil elimination.			
Section 5: Fire-Fighting Measures				
Section 5, Fire-fighting measures				
Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion.			
Extinguishing Media	Use extinguishing media appropriate to surrounding fire conditions,			

Use extinguishing media appropriate to surrounding fire conditions, such as water, fog, spray, dry chemical, regular foam, carbon dioxide.

Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when

Section 6: Accidental Release Measures

the product is exposed to fire.

Section 6, Accidental release measures

Personal Precautions	Avoid excessive contact and contact with eyes. Wear safety goggles or shield.
SDS : 195/01	Page 2 of 5

Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	This material is not known to possess additional hazards when spilled beyond those of other non-hazardous solids.
Sect	ion 7: Handling and Storage
Section 7, Handling and storage	
Handling	No special control measures required for the normal handling of this product.
Storage	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.
Section 8: Ex	posure Controls/Personal Protection
Section 8, Exposure controls/personal	protection
Wear appropriate clothing to avoid skin co	ntact. Wash hands and arms thoroughly after handling.
Section 9:	Physical and Chemical Properties
Section 9, Physical and chemical prope	orties
Physical Form	Tadalafil Tablets USP are supplied as follows:
	20 mg orange colored, round shaped, biconvex film coated tablets debossed with 'L 124' on one side and plain on other side. Bottles of 30 NDC 68180-914-06 Bottles of 60 NDC 68180-914-07
Sectio	on 10: Stability and Reactivity
Section 10, Stability and reactivity	
Stable under recommended storage condi	tions.
Section	11: Toxicological Information
Section 11, Toxicological information	
Carcinogenesis, Mutagenesis, Impairme	ent of Fertility
	Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 5–fold for mice, and 7– and 14–fold for male and female rats, respectively,
SDS : 195/01 Effective Date : 25/01/2019	Page 3 of 5

the exposures at the maximum recommended human dose (MRHD) of 40 mg.

Tadalafil was not mutagenic in the *in vitro* bacterial Ames assays or the forward mutation test in mouse lymphoma cells. Tadalafil was not clastogenic in the *in vitro* chromosomal aberration test in human lymphocytes or the *in vivo* rat micronucleus assays.

There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 6–fold for males or 17–fold for females the exposures at the MRHD of 40 mg. In beagle dogs given tadalafil daily for 3 to 12 months, there was treatment–related non–reversible degeneration and atrophy of the seminiferous tubular epithelium in the testes in 20 to 100% of the dogs that resulted in a decrease in spermatogenesis in 40 to 75% of the dogs at doses of \geq 10 mg/kg/day. Systemic exposure (based on AUC) at no–observed–adverse-effect– level (NOAEL) (10 mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 40 mg.

There were no treatment-related testicular findings in rats or mice treated with doses up to 400 mg/kg/day for 2 years.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A
IMDG - Not Regulated		
IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

SDS : 195/01 Effective Date : 25/01/2019

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.